VERA THERAPEUTICS INC (VERA) Stock Price, Quote, News and Overview
NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD
VERA Quote, Performance and Key Statistics
22.65
-0.64 (-2.75%)
The current stock price of VERA is 22.65 USD. In the past month the price increased by 13.65%. In the past year, price decreased by -37.4%.
VERA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.75 | 322.03B | ||
| AMGN | AMGEN INC | 13.35 | 149.02B | ||
| GILD | GILEAD SCIENCES INC | 14.3 | 137.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.76 | 56.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.09B | ||
| ARGX | ARGENX SE - ADR | 97.42 | 34.20B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 26.09B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.65B | ||
| NTRA | NATERA INC | N/A | 22.93B | ||
| BIIB | BIOGEN INC | 7.97 | 18.47B | ||
| INSM | INSMED INC | N/A | 18.12B |
Related stock screener links
About VERA
Company Profile
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 112 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
Company Info
VERA THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 1200
Brisbane California CALIFORNIA 14623 US
CEO: Marshall Fordyce
Employees: 112
Phone: 16507700077
VERA THERAPEUTICS INC / VERA FAQ
What is the stock price of VERA THERAPEUTICS INC today?
The current stock price of VERA is 22.65 USD. The price decreased by -2.75% in the last trading session.
What is the ticker symbol for VERA THERAPEUTICS INC stock?
The exchange symbol of VERA THERAPEUTICS INC is VERA and it is listed on the Nasdaq exchange.
On which exchange is VERA stock listed?
VERA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERA THERAPEUTICS INC stock?
20 analysts have analysed VERA and the average price target is 66.81 USD. This implies a price increase of 194.97% is expected in the next year compared to the current price of 22.65. Check the VERA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERA THERAPEUTICS INC worth?
VERA THERAPEUTICS INC (VERA) has a market capitalization of 1.44B USD. This makes VERA a Small Cap stock.
How many employees does VERA THERAPEUTICS INC have?
VERA THERAPEUTICS INC (VERA) currently has 112 employees.
What are the support and resistance levels for VERA THERAPEUTICS INC (VERA) stock?
VERA THERAPEUTICS INC (VERA) has a support level at 21.48 and a resistance level at 22.65. Check the full technical report for a detailed analysis of VERA support and resistance levels.
Should I buy VERA THERAPEUTICS INC (VERA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VERA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VERA, evaluating the profitability, health, valuation and growth aspects
- VERA THERAPEUTICS INC (VERA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERA THERAPEUTICS INC (VERA) Sales and EPS estimates to see what analysts future expectations are.
- VERA THERAPEUTICS INC (VERA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERA THERAPEUTICS INC (VERA) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERA THERAPEUTICS INC (VERA) Stock Chart to make your own analysis
- VERA THERAPEUTICS INC (VERA) Latest news and press-releases to stay up to date.
Does VERA THERAPEUTICS INC (VERA) stock pay dividends?
VERA does not pay a dividend.
When does VERA THERAPEUTICS INC (VERA) report earnings?
VERA THERAPEUTICS INC (VERA) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of VERA THERAPEUTICS INC (VERA)?
VERA THERAPEUTICS INC (VERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3).
What is the Short Interest ratio of VERA THERAPEUTICS INC (VERA) stock?
The outstanding short interest for VERA THERAPEUTICS INC (VERA) is 14.93% of its float. Check the ownership tab for more information on the VERA short interest.
VERA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VERA. When comparing the yearly performance of all stocks, VERA is a bad performer in the overall market: 89.53% of all stocks are doing better.
VERA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VERA. VERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VERA Financial Highlights
Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -3. The EPS decreased by -44.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.76% | ||
| ROE | -32.8% | ||
| Debt/Equity | 0.1 |
VERA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to VERA. The Buy consensus is the average rating of analysts ratings from 20 analysts.